Italy Unveils New Payment Model For Novartis’s CAR-T Kymriah
Executive Summary
The Italian authorities have agreed a new kind of reimbursement model for Novartis's CAR-T therapy Kymriah that involves payment in instalments depending on the patient’s response to treatment.
You may also be interested in...
NGOs Urge Italian Govt Not To Replace Head Of Drugs Agency
The Italian health ministry is looking for someone to take over as director general of the medicines agency AIFA. The move has shocked health activists who see Luca Di Bassi as a champion of drug price transparency.
Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.
Payment For Outcomes Key To EU Market Access for Yescarta
Payment for outcomes has played an important role in enabling Gilead to secure reimbursement for Yescarta in some EU markets. It is likely to be the key focus for the company as it works to expand patient access to the potentially transformative CAR-T therapy across Europe.